Biannual breath and blood marker tracking for COPD
Biannual Review of Exhaled Air and Trends in Health Evaluation in COPD
NA · Universitair Ziekenhuis Brussel · NCT07045948
This study will test whether twice-yearly breath nitric oxide (FeNO) tests and blood eosinophil counts, tracked over one year, reveal different patterns in people with COPD who have flare-ups versus those who stay stable.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Universitair Ziekenhuis Brussel (other) |
| Locations | 1 site (Jette) |
| Trial ID | NCT07045948 on ClinicalTrials.gov |
What this trial studies
Over 12 months, participants attend three visits (baseline, 6 months, 12 months) for routine lung function tests, symptom questionnaires, a simple breath nitric oxide (FeNO) test, and a small extra blood draw to measure eosinophils. The study will track how airway inflammation markers, lung function, and symptoms change over time and compare trajectories between people who experience exacerbations and those who remain stable. All procedures except the extra blood draw are part of standard COPD follow-up and participation does not change usual treatment. The goal is to map marker trends that could inform future personalized management.
Who should consider this trial
Good fit: Adults aged 40 or older with COPD by GOLD criteria who attend routine six-month follow-up visits and can give informed consent are ideal candidates, provided they have no recent exacerbation, no asthma-dominant phenotype, and no severe comorbidities.
Not a fit: People with a dominant asthmatic phenotype, a respiratory infection or exacerbation within four weeks before enrollment, or severe comorbidities preventing follow-up are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, this could help clinicians predict flare-ups and tailor COPD treatment using simple breath and blood tests.
How similar studies have performed: Prior studies have shown blood eosinophil counts can predict inhaled steroid response and exacerbation risk in COPD, while FeNO has been more informative in asthma than in COPD, so this combined approach is partly supported but still being refined.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged ≥ 40 years * Diagnosed with COPD according to GOLD criteria * Attending routine follow-up visits every 6 months * Ability to provide informed consent Exclusion Criteria: * Recent respiratory tract infection or exacerbation (either moderate or se-vere) (\<4 weeks before inclusion) * Dominant asthmatic phenotype (ACO with asthma predominance) * Severe comorbidities interfering with participation or follow-up
Where this trial is running
Jette
- Universitair Ziekenhuis Brussel — Jette, Belgium (RECRUITING)
Study contacts
- Study coordinator: Naomi Michotte, MD
- Email: pneumologie@uzbrussel.be
- Phone: 024776841
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COPD, FeNO, Blood eosinophil count